ICON and Proteome Sciences partner on biomarkers

Manjula Puthenedam, PhD, | | Health Imaging | Molecular Imaging
ICON and Proteome Sciences have formed a strategic alliance to provide pharmaceutical companies with an expanded biomarker solution to allow earlier assessments in the development of new medicines.

The Dublin-based ICON said it is including an integrated suite of labeling, separation and mass spectrometry technologies for protein and peptide profiling in complex biological materials through its alliance with Proteome's PS Biomarker Services.

ICON and Proteome Sciences are already engaged in their first joint project which is the development of a mass spectrometry assay for a key biomarker for an international pharmaceutical development company.

Manjula Puthenedam, PhD,

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.